2025 年 5 月 8 日医麦客新闻 eMedClub News根据中国国家药监局药品审评中心(CDE)官网及公开资料不完全统计,上周(4 月 28 日 - 5 月 4 日),约 18 项生物创新药 IND 获批临床默示许可/IND 申请获受理。(备注:本文仅统计双抗、ADC、CAR-T 等新分子类型生物创新药)上述新进展涉及完全缓解率为 99.1% 的双顺反子 CD19/CD22 CAR-T,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.